Case report on a BRCA2-related pancreatic adenocarcinoma. 1st line therapy included combination of gemcitabine with experimental alkylating agent, and resulted in a major tumor response. Then alkylating agent was discontinued due to toxicity, and PD was observed on single-agent gemcitabine. Experimental antiangiogenic drug was given in the 2nd line without any effect. 3rd line therapy included mitomycin C plus capecitabine, and again led to a major tumor response. The gene discussed is BRCA2; the disease is neoplasm.